SCM
MYGN icon

Scopia Capital Management’s Myriad Genetics MYGN Stock Holding History

Scopia Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,659,647
Closed -$75.3M – 44
2016
Q3 		$75.3M Sell
3,659,647
-994,680
-21% -$25.2M 1.33% 24
2016
Q2 		$142M Sell
4,654,327
-749,335
-14% -$26M 2.94% 12
2016
Q1 		$202M Sell
5,403,662
-1,055,477
-16% -$39.8M 3.77% 7
2015
Q4 		$279M Sell
6,459,139
-324,113
-5% -$13.7M 5.53% 5
2015
Q3 		$254M Buy
6,783,252
+297,026
+5% +$10.5M 5.45% 7
2015
Q2 		$220M Buy
6,486,226
+676,427
+12% +$23M 4.28% 9
2015
Q1 		$206M Buy
5,809,799
+1,633,725
+39% +$58.5M 4.45% 7
2014
Q4 		$142M Buy
4,176,074
+1,604,113
+62% +$56.9M 2.65% 13
2014
Q3 		$99.2M Sell
2,571,961
-279,306
-10% -$10.4M 2.02% 16
2014
Q2 		$111M Buy
2,851,267
+521,314
+22% +$19.4M 2.86% 13
2014
Q1 		$79.7M Buy
2,329,953
+1,567,553
+206% +$48.6M 2.53% 15
2013
Q4 		$16M Buy
+762,400
New +$19.3M 0.49% 27

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Scopia Capital Management's MYGN Position: Q4 2016 in Review

Scopia Capital Management sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 3,659,647 shares — an estimated $75.3M sold.

Scopia Capital Management first reported a position in MYGN in Q4 2013 and held it in 12 quarters. The position peaked at $279M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Scopia Capital Management reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Scopia Capital Management sold 3,659,647 Myriad Genetics shares in Q4 2016, an estimated $75.3M.
  • Scopia Capital Management first reported a position in Myriad Genetics in Q4 2013 and held it in 12 quarters.
  • Scopia Capital Management's Myriad Genetics position peaked at $279M in Q4 2015.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Scopia Capital Management's 13F filing for Q4 2016, filed 15 Feb 2017.